Zydus Lifesciences has announced a postponement in the closure of its API (Active Pharmaceutical Ingredient) business acquisition with Sterling Biotech, with the new timeline extending to June 30.

Transaction Timeline Extension

The pharmaceutical company has confirmed that both parties have mutually agreed to postpone the closure of the API business acquisition. The revised completion date has been set for June 30, extending the original timeline for the transaction completion.

Business Implications

This postponement represents a timeline adjustment in the ongoing business acquisition between the two pharmaceutical companies. The extension suggests that both Zydus Lifesciences and Sterling Biotech may require additional time to complete the necessary due diligence, regulatory approvals, or other procedural requirements associated with the API business acquisition.

The API business segment plays a crucial role in pharmaceutical manufacturing, as active pharmaceutical ingredients form the core components of finished drug products. The acquisition involves the transfer of API business operations from Sterling Biotech to Zydus Lifesciences.

Next Steps

With the new deadline established for June 30, both companies will continue working toward completing the acquisition within the extended timeframe. The postponement allows for proper completion of all regulatory and business formalities required for the API business acquisition closure.

Zydus Lifesciences has entered into a strategic partnership with Bioeq to secure US commercialization rights for Nufymco, marking a significant development in the company's international expansion strategy. The collaboration follows the successful approval of Nufymco's Biologics License Application (BLA) by the US Food and Drug Administration (FDA) on December 18, 2025.

USFDA Approval Milestone

The partnership gains particular significance with the FDA's approval of Nufymco's BLA on December 18, 2025. This regulatory clearance represents a crucial step in bringing the biologic product to the US market.

Strategic Partnership Framework

The collaboration with Bioeq positions Zydus Lifesciences to leverage specialized expertise for the US market entry of Nufymco. This partnership structure allows the company to access established distribution networks and regulatory knowledge specific to the American pharmaceutical landscape.

Market Expansion Implications

The partnership represents Zydus Lifesciences' continued focus on international market expansion through strategic alliances. By securing US rights to Nufymco through this collaboration, the company demonstrates its commitment to bringing innovative biologic treatments to American patients while leveraging partner expertise for market penetration.